<DOC>
	<DOCNO>NCT01346085</DOCNO>
	<brief_summary>Our final objective develop adoptive therapy tolerogenic donor-specific Tr1 cell T1D patient undergo pancreatic islet transplantation ( Tx ) . The achievement objective depend availability immunosuppressive treatment ( IS ) compatible survival , function , expansion transfer Tr1 cell . For purpose investigator design CNI-free single-group , phase 1-2 trial exclude ATG anti-CD25 induction therapy 1st islet infusion</brief_summary>
	<brief_title>Calcineurin Inhibitor ( CNI ) -Free Immunosuppressive Regimen T1D Patients Receiving Islet Transplantation</brief_title>
	<detailed_description>We design clinical trial single-arm , phase 1-2 trial conduct two transplant center ( San Raffaele Scientific Institute , Milan , Italy ; Cell Isolation Transplantation Center , University Geneva , Geneva , Switzerland ) use common protocol islet preparation , post-transplantation patient management data collection . The trial exploratory nature target enrollment 10 patient . The recruitment competitive two center patient receive least 10,000 IE/kg . Up three islet infusion allow per patient insulin independence reach , provide partial islet function ( i.e. , fast C-peptide ≥0.3 ng/mL ) maintain infusion . We plan individual follow-up 3 year last islet infusion . Patients type 1 diabetes eligible study . Major criterion inclusion : age 18-65 year ; type 1 diabetes onset &lt; 40 year age ; insulin treatment least 5 year time enrollment ; stimulate C-peptide response arginine &lt; 0.5 ng/ml ; multiple ( three ) daily insulin injection Continuous Subcutaneous Insulin Infusion ; self-blood glucose monitoring ≥3 times/day ; high glycemic instability and/or hypoglycemia unawareness ; inability consistently attain glycated hemoglobin target &lt; 7.5 % without severe hypoglycemia ( defined hypoglycemic episode require assistance another person resolution ) past 36 month despite medical management diabetes specialist . Major criterion exclusion : HbA1c &gt; 12 % ; BMI &gt; 30 kg/m2 , insulin requirement &gt; 0.8 IU/kg/day ; poorly control hypertension ; untreated proliferative diabetic retinopathy ; presence history macroalbuminuria ( &gt; 300mg/g day ) estimate glomerular filtration rate &lt; 60 ml/min/1.73 m2 female &lt; 70 ml/min/1.73 m2 male .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Male female patient age 1865yr ability provide write informed consent comply study protocol procedure clinical history type 1 diabetes onset &lt; 40yr age , insulin least 5yr time enrollment absent stimulate Cpeptide ( &lt; 0.5ng/ml ) response arginine multiple ( three ) daily insulin injection insulin pump therapy self blood glucose monitoring ≥3 times/day , supervise specialist physician high glycemic instability hypoglycemia unawareness inability consistently attain HbA1c &lt; 7.5 % target without experience severe hypoglycemia ( assistance another person ) past 36 month despite appropriate medical management . HbA1c &gt; 12 % BMI &gt; 30 kg/m2 , insulin requirement &gt; 0.8 IU/kg/day ; poorly control hypertension ; untreated proliferative diabetic retinopathy ; presence history macroalbuminuria ( &gt; 300mg/g day ) measure glomerular filtration rate &lt; 60 ml/min/1.73 m2 female &lt; 70 ml/min/1.73 m2 male female participant : positive pregnancy test , presently breastfeed , unwilling use effective contraceptive measure duration study 3 month discontinuation male participant : intent procreate duration study within 3 month discontinuation unwillingness use effective measure contraception ; history malignancy within previous 5 year , except completely resect squamous basal cell carcinoma skin ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>islet transplantation</keyword>
	<keyword>brittle diabetes</keyword>
	<keyword>type 1 diabetes</keyword>
</DOC>